Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus

https://doi.org/10.17749/2070-4909.2018.11.3-023-037

Full Text:

Abstract

The aim is to study the clinical and economic aspects of using belimumab for the treatment of systemic lupus erythematosus (SLe) in patients with high SLe activity, the presence of anti-DNA, a low level of complement in the blood plasma and minimal lupus organ damage at the early stage.

Materials and methods. The Markov model of SLe is used. The initial probabilities of the Markov transitions are obtained from analysis of published clinical and observational studies. The prices of the relevant drugs were obtained from the VeD price registry. Medical and nonmedical expenses are calculated on the basis of the current standards for financial costs and coefficients, as well as payments for temporary and permanent disability. Indirect costs are calculated using the method of human capital.

Results. It has been found that using belimumab leads to a decrease in costs (both direct and indirect), as well as an increase in patient survival. The total costs for belimumab vs standard therapy approximated 8.84 million rubles vs 17.72 million rubles (of which 4.05 million rubles vs 5.58 million rubles were direct costs, and 2.57 million rubles vs 2.88 million rubles were indirect medical costs) on average per patient in the belimumab group vs standard therapy group, respectively.

Conclusion. The use of belimumab in the target population of patients is pharmacoeconomically justified and expedient because it leads to increased treatment efficiency and reduction of direct and indirect costs. 

About the Authors

A. G. Tolkushin
LLC «Independent Research Company «Smart Choice» ; The Scientific and Practical Center for Clinical Research and evaluation of Medical Technologies of the Moscow City Health Department.
Russian Federation

Tolkushin Aleksandr Gennadevich – PhD, Chief expert, LLC «Smart Choice Independent Research Company; Leading Researcher, The Scientific and Practical Center for Clinical Research and evaluation of Medical Technologies, Department of Healthcare in the City of Moscow.

23/6 Otkrytoe shosse, Moscow 107143; 12-2 Minskaya Str., Moscow 121096.



N. L. Pogudina
LLC «Independent Research Company «Smart Choice».
Russian Federation

Pogudina Natalia Leonidovna – PhD, LLC «Smart Choice Independent Research Company».

23/6 Otkrytoe shosse, Moscow 107143.



References

1. Podchernyaeva N. S., Solntseva O. A., Soboleva M. K., Shcherbakova M. Yu. Pediatricheskaya farmakologiya (in Russian). 2006; 3 (6): 21-28.

2. Federal clinical guidelines for the diagnosis and treatment of systemic lupus erythematosus. Association of rheumatologists of Russia [Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu sistemnoy krasnoy volchanki. Assotsiatsiya revmatologov Rossii (in Russian)]. 2015.

3. Nasonov e. L., Reshetnyak T. M., Denisov L. N., Stanislav M. L., Solov’ev S. K. Nauchno-prakticheskaya revmatologiya. 2012; 54 (5): 13-19.

4. Chirkin A. A., Okorokov A. N., Goncharik I. I. Diagnostic guide of the therapist [Diagnosticheskiy spravochnik terapevta (in Russian)]. 1991.

5. Bruce I. N., O’Keeffe A. G., Farewell V. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep; 74 (9): 1706-13. DOI: 10.1136/annrheumdis-2013-205171.

6. Decree of the Government of the Russian Federation of December 8, 2017 No. 1492 “On the Program of State Guarantees of Free Medical Assistance to Citizens for 2018 and for the Planning Period of 2019 and 2020” (in Russian).

7. Yagudina R. I., Kulikov A. YU., Protsenko M. V. FARMAkoekoNoMIkA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAkoekoNoMIkA. Modern pharmacoeconomics and pharmacoepidemiology (in Russian). 2009; 3: 80.

8. Yagudina R. I., Serpik V. G. Farmakoekonomika: teoriya i praktika. 2016; 4 (2): 5-9.

9. Ivahnenko O. I., Avksent’eva M.V., Maksimova L. V. Meditsinskie tekhnologii. otsenka i vybor. 2013; (1): 29-35.

10. Navarra S. V., Guzman R. M., Gallacher A. e. et al., for the BLISS-52 Study Group. efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet. 2011; 377: 721-31.

11. Bruce I. N., Urowitz M., van Vollenhoven R., Aranow C. et al. Long-term organ damage accrual and safety in patients with SLe treated with belimumab plus standard of care. Lupus. 2016 Jun; 25 (7): 699-709. DOI: 10.1177/0961203315625119.

12. Jönsen A., Hjalte F., Willim M., Carlsson K. S. et al. Direct and indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic study based on five defined cohorts. Semin Arthritis Rheum. 2016 Jun; 45 (6): 684-90. DOI: 10.1016/j. semarthrit.2015.11.013.

13. Decree of the Government of the Russian Federation of December 8, 2017 No. 1492 “On the Program of State Guarantees of Free Medical Assistance to Citizens for 2018 and for the Planning Period of 2019 and 2020” (in Russian).

14. Aseeva e. A., Solov’ev S. K., Klyukvina N. G., Popkova T. V. et al. Nauchno-prakticheskaya revmatologiya. 2016; 54 (4): 404-411. https://doi.org/10.14412/1995-4484-2016-404-411.

15. Sigidin Ya. A. Work ability of patients with systemic lupus erythematosus [Trudosposobnost’ bol’nyh pri sistemnoy krasnoy volchanke (in Russian)]. [electronic resource]. URL: http://medbe.ru/ materials/sistemnaya-krasnaya-volchanka-skv/trudosposobnostbolnykh-pri-sistemnoy-krasnoy-volchanke/. Accessed: 01.03.2018.

16. Sigidin Ya. A., Guseva N. G., Ivanova M. M. Systemic lupus erythematosus. Rehabilitation of patients (in Russian). [electronic resource]. URL: http://medbe.ru/materials/sistemnaya-krasnayavolchanka-skv/sistemnaya-krasnaya-volchanka-reabilitatsiyabolnykh/. Accessed: 01.03.2018.

17. Rosstat: The report “Social and economic Situation of Russia” for 2017 is the final one (in Russian). [electronic resource]. URL: https://nangs. org/analytics/rosstat-doklad-sotsialno-ekonomicheskoe-polozhenie-rossiiza-2017-god-itogovyj-onlajn-pdf. Accessed: 01.03.2018.

18. Manzi S., Sanchez-Guerrero J., Merrill J. T. et al. effects of belimumab, a B lymphocyte stimulator-specigic inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012; 71: 1833-1838. DOI: 10.1136/annrheumdis-2011-200831.

19. van Vollenhoven R. F., Petri M. A., Cervera R., Roth D. A., Ji B. N., Kleoudis C. S., Zhong Z. J., Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug; 71 (8): 1343-9. DOI: 10.1136/annrheumdis-2011-200937.

20. Aseeva e.A., Soloviev S.K., Mesnyankina A.A., Reshetnyak T.M., Lopatina N.e., Glukhova S.I., Nasonov e.L. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Rheumatology Science and Practice. 2016; 54 (1): 31-37. (In Russian). https://doi. org/10.14412/1995-4484-2016-31-37. [electronic resource] URL: https://rsp.imaress.net/rsp/article/view/2166. Accessed: 01.03.2018.

21. Gladman D. D., Urowitz M. B., Rahman P., Ibañez D., Tam L. S. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 Sep; 30 (9): 1955-9.

22. Tarasova I. A., Ivanova M. M. Nauchno-prakticheskaya revmatologiya (in Russian). 2003; 2. [electronic resource]. URL: https://rsp. ima-press.net/rsp/article/view/907/599. Accessed: 01.03.2018.


For citation:


Tolkushin A.G., Pogudina N.L. Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(3):23-37. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.3-023-037

Views: 58


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)